Overview: Smooth Muscle Actin Immunohistochemistry TestIntroduction: The Smooth Muscle Actin Immunohistochemistry Test detects smooth muscle actin (SMA) to diagnose tumors or vascular disorders, causing lumps or pain. Aligned with 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected tumors or vascular conditions.
Other Names: SMA IHC Assay, Actin IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: SMA immunohistochemistry began in the 1980s with tumor and vascular research. Methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects SMA to diagnose tumors or vascular disorders, guides treatment, and evaluates patients with lumps or pain.
Test Parameters: 1. Smooth Muscle Actin
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lumps, pain, or vascular disorders.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lumps, pain, vascular disorders, or family history of tumors. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, tumor or vascular implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect SMA in tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for tumor or vascular diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive SMA staining suggests tumors (e.g., leiomyosarcoma) or vascular disorders, guiding surgery or therapy. Negative staining may require further testing.
Specialist Consultation: Consult an oncologist or vascular surgeon for result interpretation and treatment planning.
Additional Supporting Tests: Desmin IHC, CD34 IHC, or imaging (e.g., CT/MRI) to assess tumors or vascular disorders.
Test Limitations: Not specific to one tumor or vascular condition; clinical correlation is needed. Other markers may be required.
References: WHO Soft Tissue Tumor Guidelines, 2023; American Journal of Surgical Pathology, Miettinen M, 2022.
